Ipsen Sa · EURONEXT:IPN
Ipsen Sa — JP Morgan Healthcare Conference 2020
13 slides from Ipsen Sa's conference presentation, Jan 15, 2020
Slide 1: JP Morgan Healthcare Conference
Marin Living with fibrodysplasia ossificans progressiva Hamilton, Canada JP Morgan Healthcare Conference January 15, 2020 Aymeric Le Chatelier, CEO & CFO
Slide 2: Disclaimer & Safe Harbor
Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements in
Slide 3: Being a leading global biopharma focused on innovation and Specialty Care
Being a leading global biopharma focused on innovation and Specialty Care Sales by therapeutic area Sales by geography Q3 2019 YTD sales by therapeutic area Q3 2019 YTD sales by geographical area Neuroscience Rare Diseases North Consumer America Specialty 15% Care 3% Healthcare Europe 30% 89% 11% 11
Slide 4: Growing and transforming at Ipsen
Growing and transforming at Ipsen Industry leading Specialty Care Quickly advancing top and bottom-line #1 or #2 in key markets R&D pipeline growth Top 14 Oncology company globally 6 NCEs and multiple LCM programs High-performing Well-diversified >5,700 employees executive management geographically
Slide 5: Delivering on our growth strategy in 2019
Delivering on our growth strategy in 2019 Top line Pipeline Strong double-digit Group sales growth1 in the last 3 years2 • Acquisition of Clementia • Strong performance of Specialty Care across all key Pharmaceuticals and global licensing products and geographies agreement for BLU-782 with Blueprint
Slide 6: Growing our strong Oncology portfolio with product and pipeline expansion potential
Growing our strong Oncology portfolio with product and pipeline expansion potential Ronny Living with neuroendocrine tumors Ringwood, UK • Best-in-class SSA, superior clinical profile, positive real-world • TKI of choice and growing market share in 2L RCC evidence and new delivery system • IO combin
Slide 7: Sustaining our strong and high growth Neuroscience long-term franchise
Sustaining our strong and high growth Neuroscience long-term franchise Janice Living with cervical dystonia Tennessee, USA Therapeutics Aesthetics • Focus on spasticity indications: • Successful Galderma partnership Significant opportunity remains – only ~4.5% eligible adult spasticity patients • Gr
Slide 8: Establishing Rare Diseases leadership position in FOP
Establishing Rare Diseases leadership position in FOP Marin Living with fibrodysplasia ossificans progressiva Hamilton, Canada Portfolio strategy in FOP – ultra-rare bone disorder with no therapeutic treatment options Two potentially complementary drug candidates to offer the broadest possible suite
Slide 9: Growing and accelerating our Pipeline
Growing and accelerating our Pipeline Aiming for first/ Focus on Oncology, Be a leading external best-in-class assets Be a development Neuroscience and innovation-sourcing drives differentiation powerhouse Rare Diseases organization of the pipeline • Addressing unmet medical • Innovative programs: •
Slide 10: Advancing solid pipeline across 3 strategic TAs with 6 NCEs in clinic
Advancing solid pipeline across 3 strategic TAs with 6 NCEs in clinic and 6 significant Phase 3 / registrational trials Preclinical Phase I Phase II Phase III Registration 177Lu-IPN-01072 68Ga-IPN-01070 Longer-acting toxin (Satoreotide Tetraxetan) (Satoreotide Trizoxetan) Palovarotene Dysport® mrBoN
Slide 11: Delivering key R&D milestones in 2020
Delivering key R&D milestones in 2020 Onivyde® IPN1087 Long-acting neurotoxin (A) IPN10360 (rBoNT-E) BLU-782 Program Phase 3 Phase 1 Phase 1/2 Phase 2 Phase 2 advancements 1L PDAC Diagnostic Spasticity and aesthetics Glabellar lines FOP Cabometyx Palovarotene Dysport® Decapeptyl® Top-line 1L RCC com
Slide 12: Gearing up to 2020
Gearing up to 2020 Growth Pipeline Culture • Maximize growth and market share • Increase value of our internal pipeline by • People: Drive further transformation worldwide for differentiated best-in-class accelerating and prioritizing key internal through leadership and people Specialty Care product
Slide 13: Thank You
Marin Living with fibrodysplasia ossificans progressiva Hamilton, Canada Thank You